Abhay Joshi - 15 Mar 2022 Form 4 Insider Report for Revance Therapeutics, Inc.

Role: COO, President of R&D
Signature: /s/ Terri McDowell, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 15 Mar 2022
Net transactions value: -$41,165
Form type: 4
Filing time: 17 Mar 2022, 17:56:18 UTC
Previous filing: 17 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RVNC	Common Stock	Tax liability	$41,165	-2,607	-2.1%	$15.79	120,708	15 Mar 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock award (the "RSA") for 22,620 shares. The RSA vests in three equal annual installments from March 15, 2021, subject to Dr. Joshi's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.

Content

Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock award (the "RSA") for 22,620 shares. The RSA vests in three equal annual installments from March 15, 2021, subject to Dr. Joshi's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.